ইঙ্গিত ও ব্যবহার
Oxadel এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Acute Bacterial Skin and Skin Structure Infections (ABSSSI): 300 mg of Delafloxacin Injection every 12 hours over 60 minutes by intravenous infusion. Total Duration: 5 to 14 days.Community-Acquired Bacterial Pneumonia (CABP): 300 mg of Delafloxacin Injection every 12 hours over 60 minutes by intravenous infusion. Total Duration: 5 to 10 days.Hepatic Impairment: No dosage adjustment is necessary for Delaflox (Delafloxacin) in patients with hepatic impairment.Renal Impairment: Dosage adjustment is required for patients with severe renal impairment (eGFR 15-29 mL/min/1.73m2). In patients with severe renal impairment or ESRD (eGFR of < 15 mL/min/1.73 m2), accumulation of the intravenous vehicle, sulfobutylether-β-cyclodextrin (SBECD) occurs. Serum creatinine levels should be carefully monitored in patients in such case. If serum creatinine level increases, consider switching to oral Delafloxacin. Discontinue Delafloxacin if eGFR decreases to < 15 mL/min/1.73 m2.
পার্শ্বপ্রতিক্রিয়া
Common Side Effects: The most common side effects of Delaflox include nausea, diarrhea, headache, transaminase elevations and vomiting.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy and CNS effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). Discontinue Delameg immediately at the first signs or symptoms of any serious adverse reactionFluoroquinolones have been associated with an increased risk of tendinitis and tendon rupture in all ages. Tendinitis or tendon rupture can occur, within hours or days of starting a fluoroquinolone, or even several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally. Discontinue Delameg immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon.Fluoroquinolones have been associated with an increased risk of peripheral neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including Delameg. Discontinue Delameg immediately if the patient experiences symptoms of peripheral neuropathy.Fluoroquinolones, including Delameg, have been associated with an increased risk of psychiatric adverse reactions. Toxic psychosis; hallucinations or paranoia; depression or suicidal thoughts or acts; delirium, disorientation, confusion or disturbances in attention; anxiety, agitation or nervousness; insomnia or nightmares; memory impairment may occur. Discontinue Delameg immediately if the patient experiences symptoms.Fluoroquinolones have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), dizziness and tremors. Discontinue Delameg immediately if the patient experiences symptoms.Fluoroquinolones have neuromuscular blocking activity and may cause muscle weakness in persons with myasthenia gravis. Avoid Delameg in patients with known history of myasthenia gravis.Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, have been reported in patients receiving fluoroquinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticarial and itching. Discontinue Delameg at the first appearance of a skin rash or any other sign of hypersensitivity.Clostridium difficile-associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including Delameg, with severity ranging from mild diarrhea to fatal colitis.Increased risk of aortic aneurysm and dissection have been reported within two months following use of fluoroquinolones, particularly in elderly patients.Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or with insulin. In these patients, careful monitoring of blood glucose is recommended. Severe cases of hypoglycemia resulting in coma or death have been reported with other fluoroquinolones. If a hypoglycemic reaction occurs, discontinue Delameg immediately.Delameg can make you feel dizzy and lightheaded. Do not drive, operate machinery or do other activities that require mental alertness or coordination until you know how Delameg affects you.
নিষেধাজ্ঞা
Delafloxacin is contraindicated in patients with known hypersensitivity to Delafloxacin or any of the fluoroquinolone class of antibacterial drugs. Discontinue Delafloxacin at the first appearance of a skin rash or any other sign of hypersensitivity